123 related articles for article (PubMed ID: 35227226)
1. Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015-2016.
Nilssen Y; Brustugun OT; Eriksen MT; Guren MG; Haug ES; Naume B; Schlichting E; Møller B
BMC Cancer; 2022 Feb; 22(1):220. PubMed ID: 35227226
[TBL] [Abstract][Full Text] [Related]
2. Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015-2016.
Nilssen Y; Brustugun OT; Eriksen MT; Haug ES; Naume B; Møller B
BMC Cancer; 2020 May; 20(1):488. PubMed ID: 32473650
[TBL] [Abstract][Full Text] [Related]
3. Decreasing waiting time for treatment before and during implementation of cancer patient pathways in Norway.
Nilssen Y; Brustugun OT; Tandberg Eriksen M; Gulbrandsen J; Skaaheim Haug E; Naume B; Møller B
Cancer Epidemiol; 2019 Aug; 61():59-69. PubMed ID: 31153048
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with emergency-onset diagnosis, time to treatment and type of treatment in colorectal cancer patients in Norway.
Nilssen Y; Eriksen MT; Guren MG; Møller B
BMC Cancer; 2021 Jun; 21(1):757. PubMed ID: 34187404
[TBL] [Abstract][Full Text] [Related]
5. Waiting times and treatment following cancer diagnosis: comparison between immigrants and the Norwegian host population.
Thøgersen H; Møller B; Åsli LM; Bhargava S; Kvåle R; Fjellbirkeland L; Robsahm TE; Aaserud S; Babigumira R; Larsen IK
Acta Oncol; 2020 Apr; 59(4):376-383. PubMed ID: 31920119
[No Abstract] [Full Text] [Related]
6. Equitable access to cancer patient pathways in Norway - a national registry-based study.
Olsen F; Jacobsen BK; Heuch I; Tveit KM; Balteskard L
BMC Health Serv Res; 2021 Nov; 21(1):1272. PubMed ID: 34823515
[TBL] [Abstract][Full Text] [Related]
7. Patient experiences of waiting times in standardised cancer patient pathways in Norway - a qualitative interview study.
Solbjør M; Sand K; Ervik B; Melby L
BMC Health Serv Res; 2021 Jul; 21(1):651. PubMed ID: 34225705
[TBL] [Abstract][Full Text] [Related]
8. [Pathway times in the mammography programme before and after introduction of the breast cancer care pathway].
Tsuruda KM; Bhargava S; Akslen LA; Bjørndal H; Hofvind S
Tidsskr Nor Laegeforen; 2019 Sep; 139(12):. PubMed ID: 31502798
[TBL] [Abstract][Full Text] [Related]
9. Reasons for prolonged time for diagnostic workup for stage I-II lung cancer and estimated effect of applying an optimized pathway for diagnostic procedures.
Stokstad T; Sørhaug S; Amundsen T; Grønberg BH
BMC Health Serv Res; 2019 Sep; 19(1):679. PubMed ID: 31533705
[TBL] [Abstract][Full Text] [Related]
10. [Waiting times for cancer care in four most frequent cancers in several French regions in 2011 and 2012].
Pourcel G; Ledesert B; Bousquet PJ; Ferrari C; Viguier J; Buzyn A
Bull Cancer; 2013 Dec; 100(12):1237-50. PubMed ID: 24158562
[TBL] [Abstract][Full Text] [Related]
11. Waiting times for cancer patients in Sweden: A nationwide population-based study.
Robertson S; Adolfsson J; Stattin P; Sjövall A; Winnersjö R; Hanning M; Sandelin K
Scand J Public Health; 2017 May; 45(3):230-237. PubMed ID: 28443490
[TBL] [Abstract][Full Text] [Related]
12. Waiting time disparities in breast cancer diagnosis and treatment: a population-based study in France.
Molinié F; Leux C; Delafosse P; Ayrault-Piault S; Arveux P; Woronoff AS; Guizard AV; Velten M; Ganry O; Bara S; Daubisse-Marliac L; Tretarre B
Breast; 2013 Oct; 22(5):810-6. PubMed ID: 23473773
[TBL] [Abstract][Full Text] [Related]
13. Can we assess Cancer Waiting Time targets with cancer survival? A population-based study of individually linked data from the National Cancer Waiting Times monitoring dataset in England, 2009-2013.
Di Girolamo C; Walters S; Gildea C; Benitez Majano S; Rachet B; Morris M
PLoS One; 2018; 13(8):e0201288. PubMed ID: 30133466
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with emergency-related diagnosis, time to treatment and type of treatment in 5713 lung cancer patients.
Nilssen Y; Brustugun OT; Møller B
Eur J Public Health; 2021 Oct; 31(5):967-974. PubMed ID: 34233351
[TBL] [Abstract][Full Text] [Related]
15. Shared decision-making in standardized cancer patient pathways in Norway-Narratives of patient experiences.
Andersen-Hollekim T; Melby L; Sand K; Gilstad H; Das A; Solbjør M
Health Expect; 2021 Oct; 24(5):1780-1789. PubMed ID: 34289215
[TBL] [Abstract][Full Text] [Related]
16. Waiting for radiotherapy in Ontario.
Mackillop WJ; Fu H; Quirt CF; Dixon P; Brundage M; Zhou Y
Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):221-8. PubMed ID: 8083117
[TBL] [Abstract][Full Text] [Related]
17. Quality improvement by implementing an integrated oncological care pathway for breast cancer patients.
van Hoeve J; de Munck L; Otter R; de Vries J; Siesling S
Breast; 2014 Aug; 23(4):364-70. PubMed ID: 24582455
[TBL] [Abstract][Full Text] [Related]
18. Regional variations in cancer survival: Impact of tumour stage, socioeconomic status, comorbidity and type of treatment in Norway.
Skyrud KD; Bray F; Eriksen MT; Nilssen Y; Møller B
Int J Cancer; 2016 May; 138(9):2190-200. PubMed ID: 26679150
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy waiting times for women with breast cancer: a population-based cohort study.
Jack RH; Davies EA; Robinson D; Sainsbury R; Møller H
BMC Cancer; 2007 May; 7():71. PubMed ID: 17472746
[TBL] [Abstract][Full Text] [Related]
20. Lung cancer treatment is influenced by income, education, age and place of residence in a country with universal health coverage.
Nilssen Y; Strand TE; Fjellbirkeland L; Bartnes K; Brustugun OT; O'Connell DL; Yu XQ; Møller B
Int J Cancer; 2016 Mar; 138(6):1350-60. PubMed ID: 26421593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
